![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 5
2022
Blauvelt, Andrew; Langley, Richard G.; Lacour, Jean-Philippe; Toth, Darryl; Laquer, Vivian; Beissert, Stefan; Wollenberg, Andreas; Herranz, Pedro; Pink, Andrew E.; Peris, Ketty; Fangel, Stine; Gjerum, Le; Corriveau, Joshua; Saeki, Hidehisa; Warren, Richard B.; Simpson, Eric und Reich, Kristian
(2022):
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
In: Journal of the American Academy of Dermatology, Bd. 87, Nr. 4: S. 815-824
2021
Lebwohl, Mark; Kircik, Leon; Lacour, Jean-Philippe; Liljedahl, Monika; Lynde, Charles; Morch, Marie Holst; Papp, Kim A.; Perrot, Jean-Luc; Gold, Linda Stein; Takhar, Amrit; Thaci, Diamant; Warren, Richard B. und Wollenberg, Andreas
(2021):
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
In: Journal of the American Academy of Dermatology, Bd. 84, Nr. 5: S. 1269-1277
Wollenberg, Andreas; Thomsen, Simon Francis; Lacour, Jean-Philippe; Jaumont, Xavier und Lazarewicz, Slawomir
(2021):
Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence.
In: World Allergy Organization Journal, Bd. 14, Nr. 3, 100519
2020
Wasel, Norman; Thaci, Diamant; French, Lars E.; Conrad, Curdin; Dutronc, Yves; Gallo, Gaia; Berggren, Lovisa und Lacour, Jean-Philippe
(2020):
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
In: Dermatology and Therapy, Bd. 10, Nr. 4: S. 663-670
Staender, Sonja; Yosipovitch, Gil; Legat, Franz J.; Lacour, Jean-Philippe; Paul, Carle; Narbutt, Joanna; Bieber, Thomas; Misery, Laurent; Wollenberg, Andreas; Reich, Adam; Ahmad, Faiz und Piketty, Christophe
(2020):
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
In: New England Journal of Medicine, Bd. 382, Nr. 8: S. 706-716